X
Sanofi/Regeneron’s Dupixent could be first biologic approved for nasal polyps
https://pharmaphorum.com/news/sanofi-regenerons-dupixent-could-be-first-biologic-approved-for-nasal-polyps/
Regeneron
Regeneron/Teva pain drug fasinumab on target in phase 3
Pfizer and Eli Lilly are competitors in NGF research
Regeneron forges CAR-T R&D partnership with bluebird bio
Deal combines Regeneron’s receptor tech with CAR-T biotech’s expertise
Amgen’s Repatha gets EU cardio risk reduction label
But Sanofi/Regeneron could have advantage thanks to price cut and better data
Regeneron: Biobank project offers hope for Alzheimer’s R&D
Regeneron R&D chief hopes UK data could find new Alzheimer’s and Parkinson’s drugs
Regeneron/Bayer axe eye combination drug
Phase 2 data showed no improvement over Eylea
Regeneron ends development of RSV antibody
Regeneron dumps suptavumab after phase 3 trial failure.
